Evidence map›Paper›PMID 29085990›Full record

ArticleDiabetologia2018

Annexin A1 attenuates microvascular complications through restoration of Akt signalling in a murine model of type 1 diabetes.

Gareth S D Purvis, Fausto Chiazza, Jianmin Chen, Rodrigo Azevedo-Loiola, Lukas Martin, Dennis H M Kusters, Chris Reutelingsperger, Nikolaos Fountoulakis, Luigi Gnudi, Muhammed M Yaqoob and 3 more

RetractedOpen access · hybridAbstract readRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetologia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 59 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Annexin A1 attenuates cardiac diastolic dysfunction in mice with inflammatory arthritis.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  16. Article
  17. Article
  18. Annexin Animal Models-From Fundamental Principles to Translational Research.International journal of molecular sciences · 2021
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 4 countries.

Gareth S D PurvisQueen Mary University of London, Barts and The London School of Medicine & Dentistry, The William Harvey Research Institute, Charterhouse Square, London, EC1M 6BQ, UK.
Fausto ChiazzaUniversity of Turin, Department of Drug Science and Technology, Turin, Italy.
Jianmin ChenQueen Mary University of London, Barts and The London School of Medicine & Dentistry, The William Harvey Research Institute, Charterhouse Square, London, EC1M 6BQ, UK.
Rodrigo Azevedo-LoiolaQueen Mary University of London, Barts and The London School of Medicine & Dentistry, The William Harvey Research Institute, Charterhouse Square, London, EC1M 6BQ, UK.
Lukas MartinQueen Mary University of London, Barts and The London School of Medicine & Dentistry, The William Harvey Research Institute, Charterhouse Square, London, EC1M 6BQ, UK.
Dennis H M KustersMaastricht University, Cardiovascular Research Institute, Maastricht, the Netherlands.
Chris ReutelingspergerMaastricht University, Cardiovascular Research Institute, Maastricht, the Netherlands.
Nikolaos FountoulakisKing's College London, Cardiovascular Division, Unit for Metabolic Medicine, London, UK.
Luigi GnudiKing's College London, Cardiovascular Division, Unit for Metabolic Medicine, London, UK.
Muhammed M YaqoobQueen Mary University of London, Barts and The London School of Medicine & Dentistry, The William Harvey Research Institute, Charterhouse Square, London, EC1M 6BQ, UK.
Massimo CollinoUniversity of Turin, Department of Drug Science and Technology, Turin, Italy.
Christoph ThiemermannQueen Mary University of London, Barts and The London School of Medicine & Dentistry, The William Harvey Research Institute, Charterhouse Square, London, EC1M 6BQ, UK.
Egle SolitoQueen Mary University of London, Barts and The London School of Medicine & Dentistry, The William Harvey Research Institute, Charterhouse Square, London, EC1M 6BQ, UK. e.solito@qmul.ac.uk.ORCID 0000-0001-5279-0049
Queen Mary University of London · GBKing's College London · GBUniversity of Turin · ITMaastricht University · NLUniversity of Michigan · US

Funding

British Heart Foundation FS/13/58/30648Fondazione Italiana Sclerosi Multipla 2014/R/21The Ministry of Education, Brazil 7326/2014-09University of Turin Ricerca Locale Linea B 2015
6 · The paper itself

Abstract

aims/hypothesisMicrovascular complications in the heart and kidney are strongly associated with an overall rise in inflammation. Annexin A1 (ANXA1) is an endogenous anti-inflammatory molecule that limits and resolves inflammation. In this study, we have used a bedside to bench approach to investigate: (1) ANXA1 levels in individuals with type 1 diabetes; (2) the role of endogenous ANXA1 in nephropathy and cardiomyopathy in experimental type 1 diabetes; and (3) whether treatment with human recombinant ANXA1 attenuates nephropathy and cardiomyopathy in a murine model of type 1 diabetes.

methodsANXA1 was measured in plasma from individuals with type 1 diabetes with or without nephropathy and healthy donors. Experimental type 1 diabetes was induced in mice by injection of streptozotocin (STZ; 45 mg/kg i.v. per day for 5 consecutive days) in C57BL/6 or Anxa1

resultsPlasma levels of ANXA1 were elevated in individuals with type 1 diabetes with/without nephropathy compared with healthy individuals (66.0 ± 4.2/64.0 ± 4 ng/ml vs 35.9 ± 2.3 ng/ml; p < 0.05). Compared with diabetic wild-type (WT) mice, diabetic Anxa1 CONCLUSIONS/

interpretationOverall, these results demonstrate that ANXA1 plasma levels are elevated in individuals with type 1 diabetes independent of a significant impairment in renal function. Furthermore, in mouse models with STZ-induced type 1 diabetes, ANXA1 protects against cardiac and renal dysfunction by returning MAPK signalling to baseline and activating pro-survival pathways (Akt). We propose ANXA1 to be a potential therapeutic option for the control of comorbidities in type 1 diabetes.

Indexed as

AnimalsAnnexin A1Blotting, WesternDiabetes Mellitus, ExperimentalDiabetes Mellitus, Type 1Disease Models, AnimalEnzyme-Linked Immunosorbent AssayHumansMaleMice, Inbred C57BLMice, Knockoutp38 Mitogen-Activated Protein KinasesPhosphorylationProto-Oncogene Proteins c-aktAnnexin A1p38 Mitogen-Activated Protein KinasesProto-Oncogene Proteins c-aktAktAnnexin A1DiabetesDiabetic cardiomyopathyDiabetic nephropathyMAPKMicrovascular complicationsType 1 diabetes

Identifiers

PMID29085990
PMCPMC6448955
OpenAlexW2766485966

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.